44
Views
3
CrossRef citations to date
0
Altmetric
Experimental Pathology

Tranilast modulates fibrosis, epithelial-mesenchymal transition and peritubular capillary injury in unilateral ureteral obstruction rats

, , &
Pages 564-573 | Received 24 Dec 2009, Accepted 07 May 2010, Published online: 20 Sep 2010

References

  • Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199–210.
  • Gao X, Mae H, Ayabe N, et al Hepatocyte growth factor gene therapy retards the progression of chronic obstructive nephropathy. Kidney Int 2002; 62: 1238–1248.
  • Wu MJ, Wen MC, Chiu YT, et al Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006; 69: 2029–2036.
  • Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 2002; 13: 96–107.
  • Iwano M, Plieth D, Danoff TM, et al Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341–350.
  • Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. Br J Cancer 2008; 99: 1375–1379.
  • Zeisberg EM, Potenta SE, Sugimoto H, et al Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008; 19: 2282–2287.
  • Le Hir M, Hegyi I, Cueni-Loffing D, et al Characterization of renal interstitial fibroblast-specific protein 1/S100A4-positive cells in healthy and inflamed rodent kidneys. Histochem Cell Biol 2005; 123: 335–346.
  • Picard N, Baum O, Vogetseder A, et al Origin of renal myofibroblasts in the model of unilateral ureter obstruction in the rat. Histochem Cell Biol 2008; 130: 141–155.
  • Lin SL, Kisseleva T, Brenner DA, et al Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008; 173: 1617–1627.
  • Yoshino J, Monkawa T, Tsuji M, et al Snail1 is involved in the renal epithelial-mesenchymal transition. Biochem Biophys Res Commun 2007; 362: 63–68.
  • Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 2009; 174: 1588–1593.
  • Nishigaki T. Mast cell degranulation and its inhibition by an anti-allergic agent tranilast. An electron microscopic study. Virchows Arch B Cell Pathol Incl Mol Pathol 1988; 55: 311–322.
  • Taniguchi S, Yorifuji T, Hamada T. Treatment of linear localized scleroderma with the anti-allergic drug, tranilast. Clin Exp Dermatol 1994; 19: 391–393.
  • Akahori H, Ota T, Torita M, et al Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. J Pharmacol Exp Ther 2005; 314: 514–521.
  • Kelly DJ, Zhang Y, Gow R, et al Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol 2004; 15: 2619–2629.
  • Mifsud S, Kelly DJ, Qi W, et al Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 2003; 95: 83–91.
  • Miyajima A, Asano T, Asano T, et al Tranilast ameliorates renal tubular damage in unilateral ureteral obstruction. J Urol 2001; 165: 1714–1718.
  • Soma J, Sato K, Saito H, et al Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant 2006; 21: 2795–2799.
  • Prud'homme GJ, Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007; 87: 1077–1091.
  • Qi W, Chen X, Twigg S, et al Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells. Kidney Int 2006; 69: 989–995.
  • Chakrabarti R, Subramaniam V, Abdalla S, et al Tranilast inhibits the growth and metastasis of mammary carcinoma. Anticancer Drugs 2009; 20: 334–345.
  • Docherty NG, Calvo IF, Quinlan MR, et al Increased E-cadherin expression in the ligated kidney following unilateral ureteric obstruction. Kidney Int 2009; 75: 205–213.
  • Duffield JS. The inflammatory macrophage: a story of Jekyll and Hyde. Clin Sci (Lond) 2003; 104: 27–38.
  • Broekema M, Harmsen MC, van Luyn MJ, et al Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol 2007; 18: 165–175.
  • Kure S, Yoshie O. A syngeneic monoclonal antibody to murine Meth-A sarcoma (HepSS-1) recognizes heparan sulfate glycosaminoglycan (HS-GAG): cell density and transformation dependent alteration in cell surface HS-GAG defined by HepSS-1. J Immunol 1986; 137: 3900–3908.
  • Lamanna WC, Frese MA, Balleininger M, et al Sulf loss influences N-, 2-O-, and 6-O-sulfation of multiple heparan sulfate proteoglycans and modulates fibroblast growth factor signaling. J Biol Chem 2008; 283: 27724–27735.
  • Roussoulieres A, McGregor B, Chalabreysse L, et al Expression of VE-cadherin in peritubular endothelial cells during acute rejection after human renal transplantation. J Biomed Biotechnol 2007; 2007: 41705.
  • Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 2002; 62: 1539–1549.
  • Ohashi R, Shimizu A, Masuda Y, et al Peritubular capillary regression during the progression of experimental obstructive nephropathy. J Am Soc Nephrol 2002; 13: 1795–1805.
  • Isaji M, Miyata H, Ajisawa Y, et al Inhibition by tranilast of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF)-induced increase in vascular permeability in rats. Life Sci 1998; 63: PL71–PL74.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.